October 6, 2020

Lopinavir–Ritonavir in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A randomized open-label trial (RECOVERY trial) found that among patients admitted to hospital with COVID-19, treatment with lopinavir-ritonavir was not associated with reduction in 28-day all-cause mortality (RR=1.03, 95%CI: 0.91-1.17), duration of hospital stay (RR=0.98, 95%CI: 0.91-1.05), or progression to mechanical ventilation or death (RR=1.09, 95%CI: 0.99-1.20). 23% of patients receiving lopinavir-ritonavir died within 28 days, while 22% of patients receiving usual care died within 28 days. Results were consistent across patient subgroups.

Horby et al. (Oct 5, 2020). Lopinavir–Ritonavir in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial. The Lancet. https://doi.org/10.1016/S0140-6736(20)32013-4